US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
The US FDA declines to approve Summit's China-developed lung cancer drug after its trial misses a key survival goal, sending SMMT shares plunging overnight.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The US Food and Drug Administration has declined to approve Summit's China-developed lung cancer drug after the drug's trial missed a key survival goal, according to coverage from Investor's Business Daily. The regulatory decision marks a setback for Summit's oncology program and leaves the drug without US market authorization. Coverage from Yahoo Finance reports that SMMT stock plunged overnight following the FDA rejection, reflecting investor reaction to the regulatory outcome. The two reports together frame the event as both a clinical and financial development for the company.
Neither outlet provides the specific survival statistics, the trial's phase, the drug's name, or the company's headquarters location in the available coverage.
The sequence suggests the rejection became public after market hours, driving the overnight decline before the regulatory story received wider coverage. The stakes involve Summit's ability to bring a lung cancer therapy to US patients and the company's valuation as reflected in its share price.
What to watch next depends on disclosures Summit or the FDA may issue regarding the trial data, any potential resubmission or appeal pathway, and whether the company provides further detail on the missed survival goal. Coverage does not yet specify the drug's name, the trial phase, the magnitude of the stock decline, or Summit's next regulatory steps.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (75% supported) Updated 1d ago.
Quick answers
What did the FDA decide regarding Summit's lung cancer drug?
The FDA declined to approve Summit's China-developed lung cancer drug after its trial missed a key survival goal.
How did the market react to the FDA rejection?
SMMT stock plunged overnight following the FDA rejection, according to Yahoo Finance.
Which outlets covered the story and when?
Investor's Business Daily published on November 16, 2026 at 14:31 UTC, and Yahoo Finance published on November 15, 2026 at 23:24 UTC.
What details are not provided in the coverage?
The coverage does not specify the drug's name, trial phase, specific survival statistics, stock decline magnitude, or Summit's next steps.
Coverage (2)
- FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug Investor's Business Daily · 1d ago
- SMMT Stock Plunges Overnight On FDA Rejection Yahoo Finance · 2d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Lung scans save lives: Denver man's early screening underscores dire need for more testing
A Denver man's life-saving lung scan during Lung Cancer Awareness Month spotlights urgent calls for expanded early screening nationwide.